Azithromycin has demonstrated efficacy in diminishing neutrophil recruitment in non-CF animal models [31] infected with Pseudomonas aeruginosa and in reducing neutrophilia and interleukin (IL)-8 levels in people with bronchiolitis obliterans syndrome [32]. This evidence concerns the gene CXCL8 and cystic fibrosis.